Schor, Gary v. Abbott Laboratories

**Schor v. Abbott Laboratories: Court Rules on Drug Pricing Dispute** Gary Schor sued Abbott Laboratories over the company's pricing strategy for two HIV medications, Norvir and Kaletra. Schor claimed that Abbott's pricing practices violated antitrust laws, which are designed to prevent companies from unfairly dominating markets and harming competition. The court sided with Abbott Laboratories and dismissed the case. The judge ruled that Abbott's pricing strategy did not violate the Sherman Act, a major antitrust law. The court found that Abbott's pricing approach was not an "exclusionary practice" that illegally blocked competitors, and that it could not increase the company's monopoly profits in a way that violated antitrust rules. For workers, this case shows how difficult it can be to successfully challenge large pharmaceutical companies' pricing decisions in court. While employees might be concerned about their employer's business practices affecting medication costs, antitrust laws have specific requirements that must be met to prove a violation. The ruling suggests courts will carefully examine whether pricing strategies actually harm competition before finding antitrust violations. Workers should understand that challenging corporate pricing policies requires strong legal evidence of anti-competitive behavior.